Document Type

Article

Publication Date

2013

Publication Title

BMC Cancer

Abstract

BackgroundHumanized KS-interleukin-2 (huKS-IL2), an immunocytokine with specificity for epithelial cell adhesion molecule (EpCAM), has demonstrated favorable tolerability and immunologic activity as a single agent.MethodsPhase 1b study in patients with EpCAM-positive advanced solid tumors to determine the maximum tolerated dose (MTD) and safety profile of huKS-IL2 in combination with low-dose cyclophosphamide. Treatment consisted of cyclophosphamide (300mg/m2 on day 1), and escalating doses of h

DOI

10.1186/1471-2407-13-20

Comments

Connor, Joseph||Cristea, Mihaela||Lewis, Nancy||Lewis, Lionel||Komarnitsky, Philip||Mattiacci, Maria||Felder, Mildred||Stewart, Sarah||Harter, Josephine||Henslee-Downey, Jean||Kramer, Daniel||Neugebauer, Roland||Stupp, Roger

Share

COinS